Apple’s macOS 26.4 update adds a Terminal warning to help stop ClickFix-style attacks by flagging potentially harmful pasted ...

The top-seeded and 20th-ranked Miami RedHawks failed to advance to the Mid-American Conference tournament semifinals, falling 87-83 in the quarterfinals March 12 against eighth-seeded UMass. The ...

Apple has asked Google to investigate setting up servers in its data centers to run a future version of Siri powered by Gemini, The Information reports. Currently, Apple sends its more complex AI ...

An Ars Technica colleague recently bought a new M4 MacBook Air. I have essentially nothing bad to say about this hardware, except to point out that even in our current memory shortage apocalypse, ...

OpenClaw is the latest AI attempting to make our lives (maybe?) easier. The open-source AI assistant runs locally on your device that operates on your behalf, scanning your email inbox, messages, ...

The now-viral X post from Meta AI security researcher Summer Yue reads, at first, like satire. She told her OpenClaw AI agent to check her overstuffed email inbox and suggest what to delete or archive ...

Former Vice President Kamala Harris is said to be mulling another run for the White House, a race that would be her third attempt to become the nation’s first female president. She recently rebooted ...

Delhi defeated Bainbridge-Guilford, 43-38, in the girls basketball MAC Championship Saturday at Greene High School. The Bulldogs win the MAC Championship for the first time in program history.

When students talk about the ability to take Running Start courses during the summer, they don’t talk about credits; they talk about opportunity. For one high school student, enrolling in a summer ...

Social Security, which provides benefits to about 70 million Americans, could run out of money sooner than expected, according to a new report from the Congressional Budget Office. The Old-Age and ...

Remote-first AI coding startup Kilo doesn't think software developers should have to pledge their undying allegiance to any one development environment — and certainly not any one model or harness.

Amgen has terminated its rocatinlimab collaboration with Kyowa Kirin, walking away from the anti-OX40 antibody five years after paying $400 million for rights to the autoimmune disease drug candidate.